Highbridge Capital Management’s Stemline Therapeutics, Inc. STML Stock Holding History

Highbridge Capital Management’s Portfolio STML Stock Details STML Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2018 Q2	–	Sell	-17,500	Closed	-$268K	–	1460
2018 Q1	$268K	Buy	+17,500	New	+$273K	﹤0.01%	928
2015 Q3	–	Sell	-15,807	Closed	-$187K	–	1924
2015 Q2	$187K	Sell	15,807 -16,843	-52%	-$234K	﹤0.01%	1302
2015 Q1	$472K	Buy	32,650 +14,242	+77%	+$218K	0.01%	985
2014 Q4	$314K	Buy	+18,408	New	+$265K	﹤0.01%	952

Other funds holding STML

CCM

Consonance Capital Management New York $7.28M AUM 43.59% 1-Year Est. Return

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

LSC

Lyon Street Capital Sausalito, California $67M AUM

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return

EAM

Eventide Asset Management Boston, Massachusetts $6.05B AUM 76.64% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Citadel Advisors Miami, Florida $618B AUM 30.34% 1-Year Est. Return

Nexthera Capital New York $120M AUM 10.01% 1-Year Est. Return

Highbridge Capital Management's STML Position: Q2 2018 in Review

Highbridge Capital Management sold out of Stemline Therapeutics, Inc. (STML) in Q2 2018, closing a stake of 17,500 shares — an estimated $268K sold.

Highbridge Capital Management first reported a position in STML in Q4 2014 and held it in 4 quarters. The position peaked at $472K in Q1 2015. 91 funds tracked by Wall St. Rank hold STML as of Q2 2018.

Highbridge Capital Management reported no remaining Stemline Therapeutics, Inc. position as of Q2 2018 after selling out during the quarter.
Highbridge Capital Management sold 17,500 Stemline Therapeutics, Inc. shares in Q2 2018, an estimated $268K.
Highbridge Capital Management first reported a position in Stemline Therapeutics, Inc. in Q4 2014 and held it in 4 quarters.
Highbridge Capital Management's Stemline Therapeutics, Inc. position peaked at $472K in Q1 2015.
91 funds tracked by Wall St. Rank held Stemline Therapeutics, Inc. as of Q2 2018.

Based on Highbridge Capital Management's 13F filing for Q2 2018, filed 14 Aug 2018.